Full Year 2023 Product Sales

The following table provides the top 20 product net sales from continuing operations in 2023, as well as the change compared with 2022:

Brands
 		Net Sales
(USD m)		% change
(USD)		% change
(cc1)		Brand classification by therapeutic area or established brands
Entresto6,0353031Cardiovascular, renal and metabolic
Cosentyx4,98045Immunology
Promacta/Revolade2,269910Oncology
Kesimpta2,1719999Neuroscience
Kisqali2,0806975Oncology
Tafinlar + Mekinist1,922911Oncology
Tasigna1,848-4-3Oncology
Jakavi1,7201012Oncology
Lucentis21,475-21-20Established brands
Xolair31,46379Immunology
Ilaris1,3552022Immunology
Sandostatin1,31468Established brands
Zolgensma1,214-11-9Neuroscience
Pluvicto980262261Oncology
Gilenya2925-54-54Established brands
Exforge Group713-4-1Established brands
Galvus Group692-19-11Established brands
Diovan Group613-6-1Established brands
Lutathera6052828Oncology
Gleevec/Glivec561-25-22Established brands
  1. For an explanation of non-IFRS measures and reconciliation tables, see the Annual Report 2023 "—Non-IFRS measures as defined by Novartis.”
  2. In the first quarter of 2023 Lucentis was reclassified from other promoted brands to established brands and Gilenya was reclassified from neuroscience to established brands.
  3. Net sales reflect Xolair sales for all indications.